论文部分内容阅读
目的观察吸入布地奈德治疗慢性阻塞性肺疾病(COPD)急性加重期患者的临床疗效。方法将50例COPD急性加重期患者随机分为治疗组(25例)和对照组(25例)。两组均在常规治疗基础上每日3次雾化吸入布地奈德,治疗组每次2 mg,对照组每次1 mg。对比治疗7 d后患者症状缓解情况及第1秒钟用力呼吸容积(FEV1)、FEV1占预计值(FEV1%)、FEV1/FVC%的变化。结果治疗组临床缓解有效率明显高于对照组,P<0.05,治疗组FEV1和FEV1/FVC%较对照组明显改善(P<0.05)。结论每日吸入6 mg布地奈德对COPD急性加重期有更好的疗效,能显著缓解胸闷、喘息、气短症状,有效改善肺功能。
Objective To observe the clinical efficacy of inhaled budesonide in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods Fifty patients with acute exacerbation of COPD were randomly divided into treatment group (25 cases) and control group (25 cases). Both groups were given inhaled budesonide 3 times a day on the basis of routine treatment, the treatment group 2 mg each time, and the control group 1 mg each time. After 7 days of treatment, the patients’ symptom relief and FEV 1, FEV 1% and FEV 1 / FVC% changes were compared. Results The effective rate of clinical remission in the treatment group was significantly higher than that in the control group (P <0.05). The FEV1 and FEV1 / FVC% in the treatment group were significantly improved compared with the control group (P <0.05). Conclusions Daily 6 mg of budesonide has a better curative effect on acute exacerbation of COPD and can relieve chest tightness, wheezing and shortness of breath and effectively improve pulmonary function.